A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

Shares of Instil Bio jumped after federal regulators cleared the investigational new drug application for its tumor treatment AXN-2510. The stock was up 11% at $24.38 in early trading. Shares were ...

Instil Bio Inc. (NASDAQ:TIL) saw its stock jump 10% after the company announced that the U.S. Food and Drug Administration ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

On January 7th, 2025, DualityBio and Avenzo announced that they entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418 ...

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Provided by PR Newswire May 22, 2025, 7:44:00 PM ...

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 By Duality Biotherapeutics May 22, 2025 Updated May 22, 2025 ...

Key Takeaways EVM14, an mRNA cancer vaccine, received FDA clearance for investigational new drug application, advancing Everest's mRNA technology to global clinical trials. Preclinical studies showed ...

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its ...

Phase 2b and phase 3 trials may begin in 2025 and 2026, respectively. A new drug application is anticipated for 2029.